A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

564

Enrollment

INDUSTRY

Sponsor class

Conditions

ER+ HER2- Advanced Breast Cancer
High-grade Serous Ovarian Cancer (HGSOC)

Interventions

DRUG: AZD8421
DRUG: Camizestrant
DRUG: Ribociclib
DRUG: Palbociclib
DRUG: Abemaciclib

Sponsor

AstraZeneca